Voyager Therapeutics Inc (VYGR) was Initiated by Wells Fargo to “Outperform”. Wells Fargo advised their investors in a research report released on May 20, 2016.
In a different news, on Jan 15, 2016, Steven M Paul (CEO) purchased 10,000 shares at $14.07 per share price.
Voyager Therapeutics Inc. is a clinical-stage gene therapy company. The Company focuses on developing life-changing treatments for patients suffering from severe diseases of the central nervous system (CNS). Its product engine has generated programs for five CNS indications including advanced Parkinson’s disease; a monogenic form of amyotrophic lateral sclerosis; Friedreich’s ataxia; Huntington’s disease and spinal muscular atrophy. The Company’s gene therapy approach uses adeno-associated virus (AAV) vectors which are modified non-replicating versions of AAV and which are ideal vectors for CNS gene therapy. It is also focused on gene replacement and gene knockdown approaches. Its products are VY-AADC01 program for advanced Parkinson’s disease VY-SOD101 for a monogenic form of Amyotrophic lateral sclerosis (ALS) VY-FXN01 for Friedreich’s ataxia VY-HTT01 for Huntington’s disease and VY-SMN101 for spinal muscular atrophy (SMA).